KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Payables: 2009-2024

Historic Payables for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to $41.6 million.

  • Novavax's Payables fell 73.53% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.6 million, marking a year-over-year decrease of 56.82%. This contributed to the annual value of $41.6 million for FY2024, which is 68.65% down from last year.
  • According to the latest figures from FY2024, Novavax's Payables is $41.6 million, which was down 68.65% from $132.6 million recorded in FY2023.
  • Over the past 5 years, Novavax's Payables peaked at $541.4 million during FY2022, and registered a low of $41.6 million during FY2024.
  • For the 3-year period, Novavax's Payables averaged around $238.5 million, with its median value being $132.6 million (2023).
  • Per our database at Business Quant, Novavax's Payables skyrocketed by 1,767.08% in 2020 and then slumped by 75.51% in 2023.
  • Novavax's Payables (Yearly) stood at $54.3 million in 2020, then soared by 133.84% to $127.0 million in 2021, then surged by 326.13% to $541.4 million in 2022, then tumbled by 75.51% to $132.6 million in 2023, then plummeted by 68.65% to $41.6 million in 2024.